![]() Ethinylestradiol | |
![]() Drospirenone | |
Combination of | |
---|---|
Ethinylestradiol | Estrogen |
Drospirenone | Progestogen; Progestin; Antimineralocorticoid; Antiandrogen |
Clinical data | |
Trade names | With 30 μg ethinylestradiol: Yasmin, others With 20 μg ethinylestradiol: Yaz, Yasminelle, others |
Other names | EE/DRSP; drospirenone/estradiol; drospirenone/ethinyl estradiol |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a601050 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
KEGG |
Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand name Yasmin among others, is a combination of ethinylestradiol (EE), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used as a birth control pill to prevent pregnancy in women.[2][3][4][5][6] It is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation) in women.[3] The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others).[4][5] A formulation with levomefolic acid (vitamin B9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications.[7][8] EE/DRSP is marketed widely throughout the world.[9]
In 2021, it was the 152nd most commonly prescribed medication in the United States, with more than 3 million prescriptions.[10][11]
See also
[edit]- Ethinylestradiol/drospirenone/levomefolic acid
- Ethinylestradiol/drospirenone/prasterone
- Estradiol/drospirenone
- List of combined sex-hormonal preparations § Estrogens and progestogens
References
[edit]- ^ "Drospirenone / estradiol (Angeliq) Use During Pregnancy". Drugs.com. 6 September 2018. Retrieved 18 March 2020.
- ^ "Ethinylestradiol/Drospirenone". AdisInsight. Springer Nature Switzerland AG.
- ^ a b "Drospirenone/Ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ a b Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Yasmin" (PDF). U.S. Food and Drug Administration.
- ^ a b Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Yaz" (PDF). U.S. Food and Drug Administration. Retrieved 31 October 2017.
- ^ Keam SJ, Wagstaff AJ (2003). "Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive". Treatments in Endocrinology. 2 (1): 49–70. doi:10.2165/00024677-200302010-00005. PMID 15871554. S2CID 209144694.
- ^ "Ethinylestradiol/Drospirenone/Folic acid". AdisInsight. Springer Nature Switzerland AG.
- ^ Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Beyaz" (PDF). U.S. Food and Drug Administration.
- ^ "Drospirenone Uses, Side Effects & Warnings". Drugs.com.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Drospirenone; Ethinyl Estradiol - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
|